ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation
Open accessAbstract
ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Measurement of CgA is recommended during follow-up of patients diagnosed with NET.
“In the ENETS (European Neuroendocrine Tumor Society) guidelines [21], measurement of CgA is recommended during follow-up of patients diagnosed with NET since plasma concentrations are related to tumor burden [14,18]”
From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [21]
The Tumor-Specific Recommendations (Table 1; page not available in our copy) include CgA measurement in follow-up for several NET categories. But the table limits measurement to cases with elevated CgA at diagnosis for some categories, and the Tumor Markers section says CgA is often normal in several NET types. The recommendation is therefore narrower than the unqualified claim about patients with NET. (LLM, conf=0.83)
Experimental — accuracy not yet measuredPlasma chromogranin A (CgA) concentrations are related to tumor burden in patients with neuroendocrine tumors (NETs).
“Plasma chromogranin A (CgA) is related to tumor burden and recommended in the follow-up of patients diagnosed with neuroendocrine tumors (NETs).”
From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 44 · Cited by 136
Research works printed but not linked: 7
- Jensen KH, Hilsted L, Jensen C, et al: Chro- mogranin A is a sensitive marker of progres- sion or regression in ileo-cecal neuroendo- crine tumors. Scand J Gastroenterol 2013; 48: 70-77.
- Campana D, Nori F, Piscitelli L, et al: Chro- mogranin A: is it a useful marker of neuroen- docrine tumors? J Clin Oncol 2007; 25: 1967- 1973.
- Bajetta E, Ferrari L, Martinetti A, et al: Chro- mogranin A, neuron specific enolase, carci- noembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuro- endocrine tumors. Cancer 1999; 86: 858-865.
- Dromain C, de Baere T, Lumbroso J, et al: De- tection of liver metastases from endocrine tu- mors: a prospective comparison of soma- tostatin receptor scintigraphy, computed to- mography, and magnetic resonance imaging. J Clin Oncol 2005; 23: 70-78.
- Pfeifer A, Knigge U, Binderup T, et al: 64 Cu- DOTATATE PET for neuroendocrine tu- mors: a prospective head-to-head compari- son with 111 In-DTPA-octreotide in 112 pa- tients. J Nucl Med 2015; 56: 847-854.
- Binderup T, Knigge U, Loft A, et al: 18 F-fluo- rodeoxyglucose positron emission tomogra- phy predicts survival of patients with neuro- endocrine tumors. Clin Cancer Res 2010; 16: 978-985.
- Kubota K, Okasaki M, Minamimoto R, et al: Lesion-based analysis of (18)F-FDG uptake and (111)In-pentetreotide uptake by neuro- endocrine tumors. Ann Nucl Med 2014; 28: 1004-1010.
- Authors
- Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen van Dijkum, E., O'Toole, D., Pascher, A., Reed, N., Sundin, A., Vullierme, M.-P., & participants, A. O. A. C. C.
- Affiliations
- Copenhagen University Hospital (DK)
- Universitat Autònoma de Barcelona (ES)
- Philipps University of Marburg (DE)
- Uppsala University Hospital (SE)
- Centre Hospitalier Universitaire de Reims (FR)
- Medical University of Vienna (AT)
- Charité – Universitätsmedizin Berlin (DE)
- Hôpital Beaujon (FR)
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 105
- Issue
- 3
- Pages
- 310-319
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2590182543
- Cited by
- 136
- References
- 44
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 14 · 2023: 20 · 2022: 27 · 2021: 21 · 2020: 10 · 2019: 11 · 2018: 5 · 2017: 8 · 2016: 1
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- neuroendocrine neoplasms, follow-up care, patient documentation, standard of care, multidisciplinary tumor board, WHO classification, TNM staging, thymic neuroendocrine tumors, lung neuroendocrine tumors, gastroenteropancreatic neuroendocrine tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
